Some of these changes are beneficial when it comes to non-tumor-promoting conditions, e.g., the decrease of VEGF, TGFβ, IL6, CXCL1, CXCL9, IL1β [89], and M2-macrophage-inducing IL4 [90], as well as the increase of immuno-supportive and M1-associated IL12p70 and TNFα [91]. The gene discussed is TGFB1; the disease is neoplasm.